Edition:
United States

Insmed Inc (INSM.OQ)

INSM.OQ on NASDAQ Stock Exchange Global Select Market

15.81USD
24 Mar 2017
Change (% chg)

$0.16 (+1.02%)
Prev Close
$15.65
Open
$15.71
Day's High
$15.89
Day's Low
$15.59
Volume
93,559
Avg. Vol
120,577
52-wk High
$17.31
52-wk Low
$9.02

Latest Key Developments (Source: Significant Developments)

Insmed announces worldwide license agreement with AstraZeneca for oral DPP1 inhibitor
Wednesday, 5 Oct 2016 06:55am EDT 

Insmed Inc : Insmed will pay AstraZeneca an upfront payment of $30 million . Agreement provides AstraZeneca with option to negotiate a future agreement with Insmed for commercialization of AZD7986/ins1007 . Continue to expect patient enrollment in phase 3 study of Arikayce to conclude later this year and to report top line data in 2017 . Confirms its cash operating expense guidance for second half of 2016 of $62 million to $72 million . In a phase 1 study of healthy volunteers AZD7986 was well tolerated . Says AstraZeneca will be eligible to receive future payments totaling $120 mln in future clinical, regulatory, and sales-related milestones .Confirms its cash operating expense guidance for second half of 2016 of $62 to $72 million..  Full Article

Insmed Q2 loss per share $0.59
Thursday, 4 Aug 2016 08:02am EDT 

Insmed Inc : Q2 loss per share $0.59 . Insmed reports second quarter 2016 financial results .Q2 earnings per share view $-0.56 -- Thomson Reuters I/B/E/S.  Full Article

Insmed says withdraws marketing application for Arikayce in Europe
Wednesday, 8 Jun 2016 05:14pm EDT 

Insmed Inc : Insmed Inc - announces withdrawal of marketing authorization application for arikayce in europe . Insmed Inc says marketing application filing was based on data from co's completed phase 2 study . Insmed Inc - During may 2016 chmp meeting, the panel indicated that phase 2 study did not provide a sufficient amount of evidence to support an approval .Insmed inc says it intends to resubmit its application for arikayce when clinical data from its ongoing global phase 3 study are available..  Full Article

More From Around the Web

BRIEF-Insmed extends Arikayce intellectual property protection with issuance of new US patent

* Extends Arikayce intellectual property protection with issuance of new U.S. Patent Source text for Eikon: Further company coverage: